New Pharmaceutical Dosage Forms Used in the Treatment of Breast Cancer. Polymeric Micelles

Opriţa, Alexandru; Sevastre, Ani-Simona

doi:10.52701/monc.2020.v1i1.9

Cited by 8 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NK012 releases SN-38 via hydrolysis and does not require enzymes for metabolism. NK012 has completed phase II clinical trials for relapsed small cell lung cancer and triple-negative breast cancer [102]. More studies are needed to decide the ideal dose of NK012 to increase safety and efficacy.…”

Section: Other Similar Products In the Pipelinementioning

confidence: 99%

Polyamide/Poly(Amino Acid) Polymers for Drug Delivery

Boddu

Bhagav

Karla

et al. 2021

JFB

View full text Add to dashboard Cite

Polymers have always played a critical role in the development of novel drug delivery systems by providing the sustained, controlled and targeted release of both hydrophobic and hydrophilic drugs. Among the different polymers, polyamides or poly(amino acid)s exhibit distinct features such as good biocompatibility, slow degradability and flexible physicochemical modification. The degradation rates of poly(amino acid)s are influenced by the hydrophilicity of the amino acids that make up the polymer. Poly(amino acid)s are extensively used in the formulation of chemotherapeutics to achieve selective delivery for an appropriate duration of time in order to lessen the drug-related side effects and increase the anti-tumor efficacy. This review highlights various poly(amino acid) polymers used in drug delivery along with new developments in their utility. A thorough discussion on anticancer agents incorporated into poly(amino acid) micellar systems that are under clinical evaluation is included.

show abstract

Section: Other Similar Products In the Pipelinementioning

confidence: 99%

Polyamide/Poly(Amino Acid) Polymers for Drug Delivery

Boddu

Bhagav

Karla

et al. 2021

JFB

View full text Add to dashboard Cite

show abstract

“…Nanosystems increase the concentration of the drug selectively to the target site, while reducing side effects associated with wide drug distribution. Therefore, nanosystems were found to reduce toxic effects brought by antineoplastic agents [29]. These systems are able to identify the target tissue [30], due to surface coating, labeling, or modifications, enhancing selective uptake of the drug by target tissue [31].…”

Section: Introductionmentioning

confidence: 99%

Nano- and Crystal Engineering Approaches in the Development of Therapeutic Agents for Neoplastic Diseases

et al. 2022

View full text Add to dashboard Cite

Cancer is a leading cause of death worldwide. It is a global quandary that requires the administration of many different active pharmaceutical ingredients (APIs) with different characteristics. As is the case with many APIs, cancer treatments exhibit poor aqueous solubility which can lead to low drug absorption, increased doses, and subsequently poor bioavailability and the occurrence of more adverse events. Several strategies have been envisaged to overcome this drawback, specifically for the treatment of neoplastic diseases. These include crystal engineering, in which new crystal structures are formed to improve drug physicochemical properties, and/or nanoengineering in which the reduction in particle size of the pristine crystal results in much improved physicochemical properties. Co-crystals, which are supramolecular complexes that comprise of an API and a co-crystal former (CCF) held together by non-covalent interactions in crystal lattice, have been developed to improve the performance of some anti-cancer drugs. Similarly, nanosizing through the formation of nanocrystals and, in some cases, the use of both crystal and nanoengineering to obtain nano co-crystals (NCC) have been used to increase the solubility as well as overall performance of many anticancer drugs. The formulation process of both micron and sub-micron crystalline formulations for the treatment of cancers makes use of relatively simple techniques and minimal amounts of excipients aside from stabilizers and co-formers. The flexibility of these crystalline formulations with regards to routes of administration and ability to target neoplastic tissue makes them ideal strategies for effectiveness of cancer treatments. In this review, we describe the use of crystalline formulations for the treatment of various neoplastic diseases. In addition, this review attempts to highlight the gaps in the current translation of these potential treatments into authorized medicines for use in clinical practice.

show abstract